Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Human antibody combinations determined by epitope mapping of orthopoxvirus A33/A35 confer therapeutic protection in mice.

Created on 12 Nov 2026

Authors

Anqi Xia, Qiwei Jiang, Xiaojie Wang, Jie Liu, Jiannan Chen, Haozhe Zhao, Siyuan Sun, Wei Wu, Weiyu Jiang, Song Xue, Yi'ou Sha, Yingying Song, Qianqian Zhang, Yaming Li, Liyuan Hu, Haiyu Wang, Yiming Long, Yidan Gao, Yuru Han, Jieliang Chen, Cong Zeng, Lu Lu, Rong Zhang, Rong Xia, Zhenghong Yuan, Xiao Li, Yixiao Zhang, Qiao Wang

Published in

Science translational medicine. Volume 18. Issue 875. Pages eaeb2836. Nov 11, 2026. Epub Nov 11, 2026.

Abstract

Human infections with mpox virus (MPXV) since 2022 have resulted in more than 188,000 cases reported globally as of June 2026, highlighting the urgent need for effective therapeutics. Here, we recruited smallpox vaccinees and donors with incidental vaccinia virus (VACV) exposure and isolated a panel of human anti-A33/A35 monoclonal antibodies (mAbs) from the latter using recombinant MPXV A35 as a cross-reactive bait. These mAbs recognized four distinct nonoverlapping epitopes (epitopes 1 to 4) and one composite epitope (epitope 3 + 4) on MPXV A35 and exhibited cross-reactivity against multiple orthopoxviruses (OPXVs). Cryo-electron microscopy structural analysis revealed that the high-affinity epitope 3 + 4 mAb HD15 engages an epitope at the A35 dimer interface that is conserved across OPXVs. Combinations of mAbs targeting nonoverlapping epitopes mediated synergistic, Fc-dependent neutralization in vitro; conferred therapeutic protection against lethal VACV challenge; and reduced viral burden and disease severity after MPXV challenge in mice. Together, these findings establish a single-antigen, multiepitope strategy for the development of broadly protective therapeutics against OPXVs.

PMID:
43013679
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement